While comments from AdvaMed and the Medical Device Manufacturers Association expressed strong support for a proposal from the Centers for Medicare and Medicaid Services that would allow up to four years of Medicare coverage of Food and Drug Administration-defined breakthrough devices, both groups said commercial insurance coverage decisions should not be used as a template.
Further, both AdvaMed and MDMA want the agency to either back away from defining what should be considered reasonable and necessary for Medicare’s population of 65-year-olds and older – a...